← FDA DRUG APPROVALS

FDA ANDA · ANDA090242

GEMCITABINE HYDROCHLORIDE

Sponsor: FRESENIUS KABI USA

APPLICATION
ANDA090242
TYPE
ANDA
ORIGINAL APPROVAL
2011-05-17
LATEST ACTION
2024-09-24
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
None (Tentative Approval), Prescription

Products

GEMCITABINE HYDROCHLORIDENone (Tentative Approval)
GEMCITABINE HYDROCHLORIDE EQ 200MG BASE/VIAL · INJECTABLE · INJECTION
GEMCITABINE HYDROCHLORIDENone (Tentative Approval)
GEMCITABINE HYDROCHLORIDE EQ 1GM BASE/VIAL · INJECTABLE · INJECTION
GEMCITABINE HYDROCHLORIDEPrescription
GEMCITABINE HYDROCHLORIDE EQ 2GM BASE/VIAL · INJECTABLE · INJECTION

Approval history

2024-09-24Labeling · Supplement 8 · standardAP
2024-09-12Labeling · Supplement 4 · standardAP
2011-05-17OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →